Narcolepsy is a neurologic sleep disorder caused by autoimmune destruction of orexin/hypocretin neurons in the lateral hypothalamus. Orexin normally stabilizes wakefulness and inhibits REM intrusion; its loss produces unstable sleep-wake transitions and REM phenomena intruding into wakefulness.
The classical tetrad of narcolepsy type 1:
Excessive daytime sleepiness — uncontrollable sleep attacks, often despite adequate nighttime sleep. The sleepiness can be irresistible — patients fall asleep during conversations, while eating, while driving.
Cataplexy — brief sudden muscle weakness triggered by strong emotion (typically laughter, surprise, anger, less commonly anxiety or sadness). Patients describe knees buckling, jaw dropping, head dropping, or full collapse — without loss of consciousness. Lasts seconds to minutes, then resolves. Highly specific for type 1 narcolepsy.
Sleep paralysis — inability to move on falling asleep or waking, lasting seconds to minutes. Patient remains conscious but cannot move. Sometimes terrifying.
Hypnagogic hallucinations — vivid dreamlike experiences (visual, auditory, sometimes tactile) at sleep onset or awakening. Often confused with psychotic phenomena.
Narcolepsy types:
Type 1 (with cataplexy) — caused by orexin neuron loss, low CSF hypocretin. Cataplexy is essentially pathognomonic.
Type 2 (without cataplexy) — similar daytime sleepiness without cataplexy, often less severe orexin deficiency. Heterogeneous; some patients later develop cataplexy.
The autoimmune story: in type 1 narcolepsy, autoimmune destruction of orexin-producing neurons. Strong HLA association (DQB1*06:02). Often follows infection (notable association with H1N1 influenza and certain vaccines after 2009 pandemic). The orexin loss is permanent.
Diagnosis: polysomnography followed by Multiple Sleep Latency Test (MSLT). MSLT shows shortened sleep latency (typically <8 minutes) and sleep-onset REM periods (SOREMPs — REM occurring within 15 minutes of sleep onset) in 2 or more naps. CSF hypocretin testing (low/absent in type 1) confirms autoimmune narcolepsy in research and complex cases.
Treatment:
For excessive daytime sleepiness: stimulants — modafinil, armodafinil, methylphenidate, amphetamines. Newer agents: solriamfetol (Sunosi), pitolisant (Wakix — also helps cataplexy).
For cataplexy: sodium oxybate (Xyrem, Xywav — the calcium-magnesium-potassium-sodium oxybate salts of Xywav have lower sodium load) is the most effective. Highly regulated (Schedule III with REMS program) due to abuse potential and respiratory risk. Pitolisant (H3 antagonist) is alternative. SSRIs, SNRIs, tricyclics also reduce cataplexy frequency.
Lifestyle: scheduled brief naps (15-20 minutes) at strategic times often help. Consistent sleep schedule. Avoid driving when uncontrolled symptoms — legal implications.
Misdiagnosis is common. Many patients carry incorrect diagnoses (depression, lazy, malingering, ADHD) for years before correct diagnosis. The sleep attacks and cataplexy are dramatic when recognized but easy to dismiss without specific knowledge.
When you encounter a patient with excessive daytime sleepiness disproportionate to sleep complaints, with or without cataplexy, narcolepsy is the diagnosis to consider. Sleep study referral is appropriate. Effective treatment substantially improves quality of life.